{"pub": "yahoo", "url": "https://news.yahoo.com/poor-evidence-cannabis-improves-mental-health-study-223208216.html", "downloaded_at": "2019-10-28 23:43:40.215499+00:00", "title": "Poor evidence cannabis improves mental health: study", "language": "en", "text": "Cannabis and cannabinoids are increasingly being made available for medicinal use in North America, Britain and Australia without being subjected to standard testing processes (AFP Photo/Philippe LOPEZ)\n\nParis (AFP) - People with psychiatric disorders may want to pass on the joint -- at least until further research is done, a new Australian study suggests.\n\nThe paper, published Monday in The Lancet Psychiatry, looked at 83 previous studies conducted over almost four decades on medical cannabinoids, including products from the cannabis plant, such as leaves, buds and oils, as well as pharmaceutical-grade cannabinoids.\n\nThe authors found insufficient evidence that the products were safe and effective in treating six common disorders: depression, anxiety, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder and psychosis.\n\nCannabis and cannabinoids are increasingly being made available for medicinal use in North America, Britain and Australia without being subjected to the standard process that includes testing and scrutinising by government regulatory bodies, lead author Louisa Degenhardt told AFP.\n\n\"One of the most striking things about the spread of legislation in multiple countries permitting cannabis/cannabinoids for medicinal purposes is that this is in many instances happening outside of the regulatory frameworks that medicine development typically occurs within,\" said Degenhardt, from the National Drug and Alcohol Research Centre at the University of New South Wales in Sydney.\n\nThe study found that after chronic non-cancer pain, mental health is one of the most common reasons for using medicinal cannabinoids.\n\nBut no reviews have considered the varying effects of the different types of cannabinoids or their safety, and the only studies into long-term effects were conducted on individuals using cannabis for recreational use.\n\nIn most randomised-controlled trials of the effects of cannabinoids on depression and anxiety, the use was related to another condition, like chronic pain or multiple sclerosis.\n\nSome studies showed improvement in anxiety symptoms, but it was unclear if that effect was due to improvements in the primary condition.\n\nIn one small study of patients with psychosis, pharmaceutical THC -- the active substance in cannabis -- actually worsened symptoms.\n\n- Safety risks -\n\nThere are safety concerns as well.\n\n\"There are risks of developing dependence upon cannabis,\" said Degenhardt. \"There are also risks if someone drives while intoxicated, and there [is] evidence that people who use cannabis regularly may be at increased risk of developing depression and psychotic symptoms.\"\n\nAlso, getting the drugs via the illicit market \"carries risk of prosecution as well as unknown product content, quality and safety,\" added Tom Freeman, of the Addiction and Mental Health Group at the University of Bath.\n\nMedications that are proven to be effective and aren't addictive already exist for many of the conditions for which cannabis is being used, said Deepak Cyril D'Souza, of Yale University School of Medicine's Department of Psychiatry, who wrote a commentary on the study.\n\nA large study -- with a double-blind, randomised, placebo-controlled trial -- is the gold standard for determining the balance between a drug's efficacy and its side effects, D'Souza told AFP.\n\nUntil that is completed, \"one cannot have confidence in attributing any beneficial effects observed in a clinical trial to cannabis.\"", "description": "People with psychiatric disorders may want to pass on the joint -- at least until further research is done, a new Australian study suggests.  The paper, published Monday in The Lancet Psychiatry, looked at 83 previous studies conducted over almost four decades on medical cannabinoids, including products", "authors": [], "top_image": "https://s.yimg.com/uu/api/res/1.2/FyRY.G74IEvDcQj0D4V8aQ--~B/aD01MTA7dz03Njg7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en_us/News/afp.com/25f2f9c256650b516ef8eeed0a0854f6da779ae0.jpg", "published_at": "2019-10-28"}